Series
Aortic valve procedures
Status
Published
Date
Number of report
001
Transcatheter aortic valve implantation (TAVI)
Ask the expert
Report presents summary of the reimbursement situation in Europe for transcatheter aortic valve implantation (TAVI) for aortic stenosis. Use of both transfemoral and transapical TAVI is reviewed.
TAVI is well established technology with reimbursement available in all studied European geographies. The main payment models are diagnosis-related group (DRG) for entire hospitalization, add-on reimbursement (England, France, Italy in some regions) and fee for procedure and material (Belgium). All geographies, but Italy, have specific procedure codes for TAVI. Brand-specific reimbursement is only available in Belgium and France, while in other countries reimbursement is established for the class of devices.
Reimbursement differs for different types of access for procedure only in France, Germany and Switzerland. In Germany and Switzerland procedure with transapical access has higher reimbursement.
Complications or stroke specifically do not impact allocation to DRG and reimbursement level in any of studied countries, with exception of France.
Almost every country has implemented certain restrictions to provision of TAVI, which are limited to inoperable or operable patients at high surgical risk in majority of studied geographies.
Manufacturers of the TAVI system include:
- Abbott (previously - St. Jude Medical) (Portico)
- Boston Scientific (Lotus)
- Colibri Heart Valve
- Direct Flow Medical
- Edwards Lifesciences (Sapien)
- JenaValve
- Medtronic (CoreValve)
- Symetis
- Transcatheter Technologies
Report includes essential information about reimbursement and national funding for TAVI, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
- Summary of the reimbursement hurdle for medical technology
- Potential further developments of the reimbursement
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- France
- Germany
- Italy
- Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Table of content
1. Introduction and summary
2. Executive summary table
3. Methodology
4. Reimbursement analysis in Austria
4.1. Overview of the reimbursement system
4.2. Reimbursement for TAVI
4.2.1. Procedure coding for TAVI
4.2.2. Diagnosis coding
4.2.3. Payment mechanism and reimbursement tariffs
4.2.4. Policy considerations for TAVI
4.2.4.1. Health technology assessments by LBI-HTA
5. Reimbursement analysis in Belgium
5.1. Overview of the reimbursement system
5.2. Reimbursement for TAVI
5.2.1. Procedure coding for TAVI
5.2.2. Payment mechanism and reimbursement tariffs
5.2.3. Reimbursement framework for TAVI determined by INAMI
5.2.4. Brand-specific reimbursement for TAVI systems
5.2.5. Policy considerations for TAVI
6. Reimbursement analysis in Denmark
6.1. Overview of the reimbursement system
6.2. Reimbursement for TAVI
6.2.1. Procedure coding for TAVI
6.2.2. Diagnosis coding
6.2.3. Payment mechanism and reimbursement tariffs
7. Reimbursement analysis in England
7.1. Overview of the reimbursement system
7.2. Reimbursement for TAVI
7.2.1. Procedure coding for TAVI
7.2.2. Diagnosis coding
7.2.3. Payment mechanism and reimbursement tariffs
7.2.4. Policy considerations for TAVI
7.2.4.1. National commissioning of TAVI by NHS England
7.2.4.2. Health technology assessment of TAVI by NICE
7.2.5. Upcoming changes in TAVI reimbursement
8. Reimbursement analysis in France
8.1. Overview of the reimbursement system
8.2. Reimbursement for TAVI
8.2.1. Procedure coding for TAVI
8.2.2. Diagnosis coding
8.2.3. Payment mechanism and reimbursement tariffs
8.2.4. Brand-specific reimbursement for TAVI in France
8.2.5. Policy considerations for TAVI
8.2.5.1. Health technology assessments by HAS
9. Reimbursement analysis in Germany
9.1. Overview of the reimbursement system
9.2. Reimbursement for TAVI
9.2.1. Procedure coding for TAVI
9.2.2. Diagnosis coding
9.2.3. Payment mechanism and reimbursement tariffs
9.2.4. Policy considerations for TAVI
9.2.4.1. Quality assurance framework for TAVI, determined by G-BA
10. Reimbursement analysis in Italy
10.1. Overview of the reimbursement system
10.2. Reimbursement for TAVI
10.2.1. Procedure coding for TAVI at national level
10.2.2. Procedure coding for TAVI at regional level
10.2.3. Diagnosis coding
10.2.4. Payment mechanism and reimbursement tariffs at national level
10.2.5. Payment mechanism and reimbursement tariffs at regional level
11. Reimbursement analysis in the Netherlands
11.1. Overview of the reimbursement system
11.2. Reimbursement for TAVI
11.2.1. Procedure coding for TAVI
11.2.2. Diagnosis coding
11.2.3. Payment mechanism and reimbursement tariffs
11.2.4. Policy considerations for TAVI
12. Reimbursement analysis in Norway
12.1. Overview of the reimbursement system
12.2. Reimbursement for TAVI
12.2.1. Procedure coding for TAVI
12.2.2. Diagnosis coding
12.2.3. Payment mechanism and reimbursement tariffs
12.2.4. Policy considerations for TAVI
12.2.4.1. Assessment of TAVI within national framework of managed introduction of innovations
13. Reimbursement analysis in Sweden
13.1. Overview of the reimbursement system
13.2. Reimbursement for TAVI
13.2.1. Procedure coding for TAVI
13.2.2. Diagnosis coding
13.2.3. Payment mechanism and reimbursement tariffs
13.2.4. Policy considerations for TAVI
13.2.4.1. Recommendations for TAVI in the national clinical guidelines
14. Reimbursement analysis in Switzerland
14.1. Overview of the reimbursement system
14.2. Reimbursement for TAVI
14.2.1. Procedure coding for TAVI
14.2.2. Diagnosis coding
14.2.3. Payment mechanism and reimbursement tariffs
14.2.4. Policy considerations for TAVI
14.2.4.1. Restrictions for TAVI in the Health Benefit List
15. Disclaimer
06
Jul 2021
In June 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (laser lithotripsy for difficult-to-treat bile duct stones and percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve), one new Medical Technologies Guidance (Plus Sutures for preventing surgical site infection), and four new Medtech Innovation Briefings (RapidAI for analyzing CT/MRI brain scans, WoundExpress, Magtrace and Sentimag, and SYNE-COV). Also, four clinical guidelines were updated, and two new published.
Read more05
May 2021
Transcatheter aortic valve implantation (TAVI/TAVR) in severe aortic stenosis treatment across all surgical risk groups was being evaluated within the "New Methods" framework since 2019. On April 26, 2021, the Decision Forum for "New Methods" made a positive coverage decision for TAVI/TAVR to treat patients with severe aortic stenosis across all surgical risk groups.
Read more27
Nov 2020
On October 30, 2020, the Swiss Federal Statistics Office (UFS) published the 2021 version of the procedure code (CHOP) nomenclature in French and Italian. The version in the German language was published in July 2020. The most important changes regard cardiovascular and peripheral vascular interventions.
Read more12
Oct 2020
On September 30, 2020, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) published the position that transcatheter aortic valve implantation (TAVI) in patients with aortic stenosis and a high risk of surgery is eligible for reimbursement under basic health insurance package.
Read more25
Sep 2020
In late august 2020, the Basic Package Advisory Committee of the Dutch Health Care Institute (ZIN) concluded that Transcatheter Aortic Valve Implantation (TAVI) complies with the ‘state of the art and science’ and is therefore effective.
Read more